Genetically engineered T cells for the treatment of cancer
2013 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 273, no 2, 166-181 p.Article, review/survey (Refereed) Published
T cell immunotherapy is a promising approach to treat disseminated cancer. However, it has been limited by the ability to isolate and expand T cells restricted to tumour-associated antigens. Using ex vivo gene transfer, T cells from patients can be genetically engineered to express a novel T cell receptor or chimeric antigen receptor to specifically recognize a tumour-associated antigen and thereby selectively kill tumour cells. Indeed, genetically engineered T cells have recently been successfully used for cancer treatment in a small number of patients. Here we review the recent progress in the field, and summarize the challenges that lie ahead and the strategies being used to overcome them.
Place, publisher, year, edition, pages
2013. Vol. 273, no 2, 166-181 p.
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-187587DOI: 10.1111/joim.12020ISI: 000313869400007PubMedID: 23198862OAI: oai:DiVA.org:uu-187587DiVA: diva2:575234